Retrospective single-center review of 80 HFrEF patients added SGLT2 inhibitors on stable guideline-directed therapy, with ...

New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.

From overtreating good-risk patients to searching for a cure, Adam Kittai, MD, Perlmutter Cancer Center, outlines where CLL ...

CDC ended the federal response June 24, 2026, after risk diminished, releasing >100 deployed staff from the peak incident management assignment. Aboard MV Hondius, 12 confirmed and 1 probable Andes ...

Bhavana “Tina” Bhatnagar, DO, reflects on AML’s transformation from few treatment options to targeted therapies and efforts to increase access to them. Acute myeloid leukemia (AML) has historically ...

Claims-based ATTR-CM incidence increased >4-fold in Medicare (2010–2021) and ~2.7-fold in commercial insurance (2016–2022), with parallel multi-fold prevalence increases across databases. Higher rates ...

Abnormal creatinine in CKD can justify SGLT2 inhibitor initiation irrespective of diabetes status, given robust renal and ...

Integrin β6 is expressed in ~90% of NSCLC and correlates with poor prognosis, supporting development of a selective, rapidly internalizing ADC designed to reduce off-target integrin binding.

Flatiron Telescope uses AI and transparent SQL to turn real-world evidence into quick turnaround oncology research and ...

FDA cleared generic rifapentine for active pulmonary TB (≥12 years) with susceptible isolates, requiring combination therapy with other active antitubercular agents. Authorization also covers LTBI (≥2 ...

Familial pulmonary fibrosis represented 13% of fibrotic ILD overall, with higher proportions in IPF (18%) and unclassifiable ILD (15%) than in SARD-ILD (9%). Across diagnostic subgroups, familial ...

Tebipenem pivoxil becomes the only FDA-approved oral carbapenem for complicated UTIs/pyelonephritis in adults lacking viable ...